Kala Pharmaceuticals Stock Forecast, Price & News

Kala Pharmaceuticals (NASDAQ:KALA) Frequently Asked Questions

Is Kala Pharmaceuticals a buy right now?

4 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Kala Pharmaceuticals in the last year. There are currently 1 hold rating and 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Kala Pharmaceuticals stock.
View analyst ratings for Kala Pharmaceuticals or view top-rated stocks.

What stocks does MarketBeat like better than Kala Pharmaceuticals?

Wall Street analysts have given Kala Pharmaceuticals a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Kala Pharmaceuticals wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

When is Kala Pharmaceuticals' next earnings date?

Kala Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Thursday, November 4th 2021.
View our earnings forecast for Kala Pharmaceuticals.

How were Kala Pharmaceuticals' earnings last quarter?

Kala Pharmaceuticals, Inc. (NASDAQ:KALA) issued its quarterly earnings results on Thursday, August, 5th. The company reported ($0.57) EPS for the quarter, missing the Thomson Reuters' consensus estimate of ($0.46) by $0.11. The firm earned $3.05 million during the quarter, compared to analysts' expectations of $5.05 million. Kala Pharmaceuticals had a negative net margin of 1,169.09% and a negative trailing twelve-month return on equity of 125.94%.
View Kala Pharmaceuticals' earnings history.

How has Kala Pharmaceuticals' stock price been impacted by Coronavirus (COVID-19)?

Kala Pharmaceuticals' stock was trading at $7.63 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, KALA stock has decreased by 61.3% and is now trading at $2.95.
View which stocks have been most impacted by COVID-19.

What price target have analysts set for KALA?

4 brokers have issued 1 year price targets for Kala Pharmaceuticals' shares. Their forecasts range from $11.00 to $47.00. On average, they anticipate Kala Pharmaceuticals' share price to reach $25.00 in the next year. This suggests a possible upside of 747.5% from the stock's current price.
View analysts' price targets for Kala Pharmaceuticals or view top-rated stocks among Wall Street analysts.

Who are Kala Pharmaceuticals' key executives?

Kala Pharmaceuticals' management team includes the following people:

• Mark T. Iwicki, Chairman, President & Chief Executive Officer (LinkedIn Profile)
• Todd Bazemore, Chief Operating Officer
• Mary E. Reumuth, Chief Financial Officer, Controller & Treasurer
• Hongming Chen, Chief Scientific Officer (LinkedIn Profile)
• Romulus Kim Brazzell, Chief Medical Officer

What is Mark Iwicki's approval rating as Kala Pharmaceuticals' CEO?

1 employees have rated Kala Pharmaceuticals CEO Mark Iwicki on Glassdoor.com. Mark Iwicki has an approval rating of 100% among Kala Pharmaceuticals' employees. This puts Mark Iwicki in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

Who are some of Kala Pharmaceuticals' key competitors?

Some companies that are related to Kala Pharmaceuticals include Oramed Pharmaceuticals (ORMP), Lexicon Pharmaceuticals (LXRX), Amryt Pharma (AMYT), Eagle Pharmaceuticals (EGRX), AnaptysBio (ANAB), OrganiGram (OGI), Veru (VERU), Collegium Pharmaceutical (COLL), Mersana Therapeutics (MRSN), PyroGenesis Canada (PYR), Rhythm Pharmaceuticals (RYTM), Emisphere Technologies (EMIS), Imago BioSciences (IMGO), Silence Therapeutics (SLN) and POINT Biopharma Global (PNT).
View all of KALA's competitors.

What other stocks do shareholders of Kala Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Kala Pharmaceuticals investors own include Pfizer (PFE), Sorrento Therapeutics (SRNE), Dynavax Technologies (DVAX), Micron Technology (MU), Inovio Pharmaceuticals (INO), VBI Vaccines (VBIV), Amarin (AMRN), Bristol-Myers Squibb (BMY), NVIDIA (NVDA) and AbbVie (ABBV).

When did Kala Pharmaceuticals IPO?

(KALA) raised $90 million in an initial public offering (IPO) on Thursday, July 20th 2017. The company issued 6,000,000 shares at $14.00-$16.00 per share. J.P. Morgan and BofA Merrill Lynch acted as the underwriters for the IPO and Wells Fargo Securities and Wedbush PacGrow were co-managers.

What is Kala Pharmaceuticals' stock symbol?

Kala Pharmaceuticals trades on the NASDAQ under the ticker symbol "KALA."

Who are Kala Pharmaceuticals' major shareholders?

Kala Pharmaceuticals' stock is owned by many different institutional and retail investors. Top institutional investors include BlackRock Inc. (5.72%), Vanguard Group Inc. (3.39%), Caxton Corp (2.62%), State Street Corp (1.27%), Geode Capital Management LLC (1.16%) and Northern Trust Corp (0.75%). Company insiders that own Kala Pharmaceuticals stock include Hongming Chen, Mark T Iwicki, Rajeev M Shah and Todd Bazemore.
View institutional ownership trends for Kala Pharmaceuticals.

Which major investors are selling Kala Pharmaceuticals stock?

KALA stock was sold by a variety of institutional investors in the last quarter, including Millennium Management LLC, Susquehanna International Group LLP, Nuveen Asset Management LLC, Cubist Systematic Strategies LLC, Ensign Peak Advisors Inc, Dimensional Fund Advisors LP, Group One Trading L.P., and Citadel Advisors LLC. Company insiders that have sold Kala Pharmaceuticals company stock in the last year include Hongming Chen, Mark T Iwicki, and Todd Bazemore.
View insider buying and selling activity for Kala Pharmaceuticals or view top insider-selling stocks.

Which major investors are buying Kala Pharmaceuticals stock?

KALA stock was purchased by a variety of institutional investors in the last quarter, including BlackRock Inc., Caxton Corp, State Street Corp, Morgan Stanley, Morgan Stanley, Vanguard Group Inc., Maverick Capital Ltd., and Goldman Sachs Group Inc.. Company insiders that have bought Kala Pharmaceuticals stock in the last two years include Rajeev M Shah, and Todd Bazemore.
View insider buying and selling activity for Kala Pharmaceuticals or or view top insider-buying stocks.

How do I buy shares of Kala Pharmaceuticals?

Shares of KALA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Kala Pharmaceuticals' stock price today?

One share of KALA stock can currently be purchased for approximately $2.95.

How much money does Kala Pharmaceuticals make?

Kala Pharmaceuticals has a market capitalization of $191.66 million and generates $6.36 million in revenue each year. The company earns $-104,330,000.00 in net income (profit) each year or ($1.99) on an earnings per share basis.

How many employees does Kala Pharmaceuticals have?

Kala Pharmaceuticals employs 188 workers across the globe.

What is Kala Pharmaceuticals' official website?

The official website for Kala Pharmaceuticals is www.kalarx.com.

Where are Kala Pharmaceuticals' headquarters?

Kala Pharmaceuticals is headquartered at 490 ARSENAL WAY SUITE 120, WATERTOWN MA, 02472.

How can I contact Kala Pharmaceuticals?

Kala Pharmaceuticals' mailing address is 490 ARSENAL WAY SUITE 120, WATERTOWN MA, 02472. The company can be reached via phone at (781) 996-5252 or via email at [email protected].